Use of a cross-linked polyethyleneimine as a tumor protein antigen vaccine carrier

A technology of polyethyleneimine and tumor protein, which is applied in the direction of anti-tumor drugs, antibody medical ingredients, medical preparations of non-active ingredients, etc., and can solve the problems of PEI cannot be degraded and application restrictions

Active Publication Date: 2019-03-22
SHANGHAI JIAOTONG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, hydrophobic PEI cannot be degraded in vivo, which limits its further application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of a cross-linked polyethyleneimine as a tumor protein antigen vaccine carrier
  • Use of a cross-linked polyethyleneimine as a tumor protein antigen vaccine carrier
  • Use of a cross-linked polyethyleneimine as a tumor protein antigen vaccine carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] In this example, the degradable PEI containing imine bonds synthesized by small molecular weight PEI and DTBP was used as the antigen carrier material. For the synthesis method, refer to the literature (M.A.Gosselin, W.Guo, and R.J.Lee, "Efficient genetransfer using reversibly cross-linked low molecular weightpolyethyleneimine, "Bioconjugate Chemistry, vol. 12, no. 6, pp. 989-994, 2001.).

[0039] The specific steps for the preparation of the composite nanoparticles of the present embodiment are as follows:

[0040] 1. Cross-link PEI and DTBP to form a degradable PEI polymer with a molecular weight of 1000Da containing disulfide bonds (hereinafter referred to as PEI-DS) dissolved in ddH 2 In O, make a 0.2mg / mL stock solution; make OVA a 5mg / mL stock solution with 10mM HEPES buffer at pH 7.4;

[0041] 2. Add the same volume of 5 mg / mL OVA solution to 0.2 mg / mL PEI-DS solution under vortex conditions, and mix them evenly to obtain composite nanoparticles.

[0042] The i...

Embodiment 2

[0058] The synthesis method used in this example is the same as in Example 1, except that the weight average molecular weight of the small molecular weight PEI used in this example is 1000Da, and the weight average molecular weight of the synthesized polymer polymer is 50000Da.

[0059] PEI-DS / OVA composite nanoparticles were prepared according to the same method as in Example 1, and the measured particle diameter was 280nm, and the potential was -16mv. Cytotoxicity assays such as Figure 7 As shown, the antigen cross-presentation experiment was performed as Figure 8 shown. It can be seen from the figure that the antigen cross-presentation effect of the prepared complex nanoparticles is 3 times that of PEI25KDa, and the proportion of living cells is increased by 51%.

[0060] The antitumor effect of composite nanoparticles such as Figure 9 and Figure 10 As shown, the smaller the tumor after 7 days, the better the effect, and the higher the mouse survival rate, the bette...

Embodiment 3

[0062] The synthesis method used in this example is the same as Example 1, except that the weight average molecular weight of the small molecular weight PEI used in this example is 2000Da, and the weight average molecular weight of the synthesized polymer polymer is 100000Da.

[0063] PEI-DS / OVA composite nanoparticles were prepared according to the same method as in Example 1, and the measured particle diameter was 280nm, and the potential was -16mv. Cytotoxicity assays such as Figure 11 As shown, the antigen cross-presentation experiment was performed as Figure 12 shown. It can be seen from the figure that the antigen cross-presentation effect of the prepared complex nanoparticles is 3.7 times higher than that of PEI25KDa, and the corresponding ratio of living cells is increased by 54%.

[0064] The antitumor effect of composite nanoparticles such as Figure 13 and Figure 14 As shown, the smaller the tumor after 7 days, the better the effect, and the higher the mouse ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides application of crosslinked polyethylenimine as an oncoprotein antigen vaccine vector, and overcomes the problem that protein antigen after penetration into the body can be degraded easily by enzyme, leading to weak immunogenicity of the vaccine. In an aqueous solution, the polymer material is capable of forming a complex antigen nanoparticle with antigen, in order to achieve loading of tumor protein antigen. The present invention uses RF33.70 as a target cell model, OVA as a model antigen, and C57BL / 6 mice bone marrow-derived dendritic cells as antigen cross presenting cells, and detects the antigen cross-presentation, cytotoxicity and in vivo anti-tumor effect of the complex nanoparticles formed by biodegradable PEI as the antigen vector and the OVA.

Description

technical field [0001] The invention relates to the direction of tumor immunotherapy in the technical field of molecular pharmacy, in particular to the use of a cross-linked polyethyleneimine as a protein antigen vaccine carrier. Background technique [0002] Tumor vaccine is an important means of tumor immunotherapy. Tumor vaccines activate the immune system, enhance the immune system's ability to recognize tumor antigens, improve the immune microenvironment, and induce the body's specific cellular and humoral immune responses, thereby preventing the growth, spread, and recurrence of tumors, and ultimately eradicating or controlling them. tumor. Research and development of vaccines and their carriers and adjuvants that are safe and can effectively stimulate the body's cellular and humoral immunity are the key issues in the development of most vaccines. [0003] The mechanism of action of tumor antigen vaccine is to use tumor antigens to activate the immune system, generat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/34A61K39/00A61P35/00
Inventor 闫婉颖陈剑徐宇虹曾垂宇商鼎王辉邱瑶
Owner SHANGHAI JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap